Artiva CFO departs; CEO assumes financial duties; Miralles becomes President

Artiva Biotherapeutics, Inc.

CFO Thad Huston to leave May 22; receives $135k cash severance and 9 months COBRA; search begun.
CEO Fred Aslan becomes principal financial and accounting officer after stepping down as President.
Diego Miralles resigns from board, appointed President and Head of R&D; $600k salary, 45% bonus target.
Miralles awarded inducement equity: 232,500 options and 77,500 RSUs under 2025 Inducement Plan.
Board size reduced from 8 to 7; Miralles's consulting agreement ended May 17.

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Diego Miralles

Director

ARTV · Artiva Biotherapeutics, Inc.

Effective: 2026-05-18
Filed: May 19, 2026 12:07 UTC

On May 18, 2026, Diego Miralles, M.D. resigned as a member of the Board of Directors (the “Board”) of Artiva Biotherapeutics, Inc. (the “Company”), effective May 18, 2026

Role change

Fred Aslan

principal financial officer and principal accounting officer

ARTV · Artiva Biotherapeutics, Inc.

Effective: 2026-05-18
Successor: Diego Miralles
Filed: May 19, 2026 12:07 UTC

On May 18, 2026 (the “Effective Date”), Fred Aslan, M.D. resigned as President of the Company in connection with Dr. Miralles’s appointment as President and Head of Research and Development of the Company as described below.

Departed

Thad Huston

Chief Financial Officer

ARTV · Artiva Biotherapeutics, Inc.

Effective: 2026-05-22
Filed: May 19, 2026 12:07 UTC

On May 18, 2026, Thad Huston and the Company agreed to Mr. Huston’s separation from his position as Chief Financial Officer and principal financial and accounting officer of the Company, effective May 22, 2026

Source: SEC EDGAR

accession 0001193125-26-229714

view filing index on sec.gov

view primary document

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.